Search
Ilaprazole
go.drugbank.com/drugs/DB11964InvestigationalIlaprazole has been investigated in Helicobacter Infections.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesNirogacestat
go.drugbank.com/drugs/DB12005ApprovedInvestigationalNirogacestat is a small-molecule gamma-secretase inhibitor that was investigated as a potential treatment for desmoid tumors. Desmoid tumors are typically characterized by aberrant activation in Notch signaling. Interaction between the n...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSarecycline
go.drugbank.com/drugs/DB12035ApprovedInvestigationalSarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II ...
Categories: P-glycoprotein inhibitorsIberdomide
go.drugbank.com/drugs/DB12101InvestigationalIberdomide is an orally administered cereblon-modulating protein degrader (CELMoD) used to treat multiple myeloma. It binds cereblon, the substrate-recognition component of an E3 ubiquitin ligase complex, and drives the ubiquitination an...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesDefactinib
go.drugbank.com/drugs/DB12282ApprovedInvestigationalDefactinib is a small molecule kinase inhibitor targeted against focal adhesion kinase (FAK) and proline-rich tyrosine kinase-2 (Pyk2), the two members of the FAK family of nonreceptor tyrosine kinases. FAK is important for the integrin-...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InducersDoravirine
go.drugbank.com/drugs/DB12301ApprovedInvestigationalDoravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) intended to be administered in combination with other antiretroviral medicines. Doravirine is available by itself or as a combination product of doravirine (10...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesRucaparib
go.drugbank.com/drugs/DB12332ApprovedInvestigationalRucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of a...
Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitorsSeladelpar
go.drugbank.com/drugs/DB12390ApprovedInvestigationalSeladelpar is a peroxisome proliferator-activated receptor (PPAR)-delta (δ) agonist. Seladelpar is a single enantiomer of the R-configuration. On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment o...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesRimegepant
go.drugbank.com/drugs/DB12457ApprovedInvestigationalRimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commissio...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesFedratinib
go.drugbank.com/drugs/DB12500ApprovedInvestigationalFedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis. It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval o...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors